Eledon Common Stock Shares Outstanding vs Short Long Term Debt Total Analysis

ELDN Stock

USD 3.12 0.10 3.31%

Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Common Stock Shares Outstanding and its Short Long Term Debt Total accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

Common Stock Shares Outstanding vs Short Long Term Debt Total

Common Stock Shares Outstanding vs Short Long Term Debt Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Common Stock Shares Outstanding account and Short Long Term Debt Total. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Eledon Pharmaceuticals' Common Stock Shares Outstanding and Short Long Term Debt Total is -0.53. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Common Stock Shares Outstanding and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Eledon Pharmaceuticals are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Common Stock Shares Outstanding i.e., Eledon Pharmaceuticals' Common Stock Shares Outstanding and Short Long Term Debt Total go up and down completely randomly.

Correlation Coefficient

-0.53

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Short Long Term Debt Total

Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Eledon Pharmaceuticals reported last year Tax Provision of (579,000). As of the 21st of May 2024, Enterprise Value is likely to grow to about 74.2 M, while Selling General Administrative is likely to drop about 10.4 M.

Eledon Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock Total Equity	Common Stock	Short Term Investments	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Other Assets
Total Assets		0.31	0.49	0.94	0.53	-0.76	-0.44	0.66	0.76	0.85	-0.03	0.91	0.48	-0.31	0.48	0.8	-0.28	0.53	0.92	-0.15	-0.04	-0.18	-0.41	0.79	0.28	0.59
Other Current Liab	0.31		0.79	0.27	0.51	-0.22	-0.29	0.49	0.21	0.11	-0.21	0.43	0.28	-0.07	0.48	0.27	-0.03	0.51	0.44	0.07	0.1	0.33	0.02	0.16	0.13	-0.18
Total Current Liabilities	0.49	0.79		0.51	0.75	-0.32	-0.65	0.75	0.32	0.3	-0.32	0.56	0.44	-0.33	0.72	0.66	-0.27	0.75	0.57	0.14	0.15	0.06	-0.01	0.35	0.15	-0.13
Total Stockholder Equity	0.94	0.27	0.51		0.56	-0.75	-0.41	0.68	0.75	0.76	0.18	0.89	0.41	-0.61	0.46	0.82	-0.58	0.56	0.89	-0.29	-0.23	-0.4	-0.51	0.73	0.17	0.56
Property Plant And Equipment Net	0.53	0.51	0.75	0.56		-0.22	-0.58	0.78	0.23	0.53	-0.05	0.39	0.58	-0.37	0.62	0.74	-0.33	1.0	0.41	-0.18	-0.15	-0.29	-0.38	0.56	0.16	-0.08
Net Debt	-0.76	-0.22	-0.32	-0.75	-0.22		-0.05	-0.47	-1.0	-0.38	0.01	-0.87	0.08	0.39	0.01	-0.38	0.37	-0.22	-0.86	-0.08	0.06	0.25	0.08	-0.33	0.31	-0.59
Retained Earnings	-0.44	-0.29	-0.65	-0.41	-0.58	-0.05		-0.46	0.04	-0.57	0.28	-0.34	-0.83	0.08	-0.91	-0.77	0.03	-0.58	-0.36	0.06	-0.18	-0.06	0.25	-0.63	-0.71	0.1
Accounts Payable	0.66	0.49	0.75	0.68	0.78	-0.47	-0.46		0.47	0.6	-0.14	0.56	0.49	-0.38	0.48	0.71	-0.33	0.78	0.57	-0.12	-0.15	-0.25	-0.33	0.66	0.06	0.23
Cash	0.76	0.21	0.32	0.75	0.23	-1.0	0.04	0.47		0.38	-0.01	0.87	-0.08	-0.39	0.0	0.39	-0.38	0.23	0.86	0.08	-0.05	-0.26	-0.08	0.33	-0.32	0.58
Non Current Assets Total	0.85	0.11	0.3	0.76	0.53	-0.38	-0.57	0.6	0.38		0.07	0.61	0.77	-0.09	0.58	0.77	-0.07	0.53	0.62	-0.38	-0.21	-0.22	-0.63	0.96	0.54	0.48
Non Currrent Assets Other	-0.03	-0.21	-0.32	0.18	-0.05	0.01	0.28	-0.14	-0.01	0.07		-0.11	-0.04	-0.51	-0.21	-0.05	-0.55	-0.05	-0.11	-0.88	-0.88	-0.7	-0.73	0.14	-0.08	0.12
Cash And Short Term Investments	0.91	0.43	0.56	0.89	0.39	-0.87	-0.34	0.56	0.87	0.61	-0.11		0.27	-0.36	0.41	0.64	-0.32	0.39	1.0	0.05	0.05	-0.07	-0.17	0.55	0.09	0.54
Common Stock Shares Outstanding	0.48	0.28	0.44	0.41	0.58	0.08	-0.83	0.49	-0.08	0.77	-0.04	0.27		0.08	0.85	0.65	0.11	0.58	0.29	-0.37	-0.11	0.02	-0.53	0.8	0.8	-0.11
Non Current Liabilities Total	-0.31	-0.07	-0.33	-0.61	-0.37	0.39	0.08	-0.38	-0.39	-0.09	-0.51	-0.36	0.08		-0.11	-0.43	1.0	-0.37	-0.37	0.38	0.46	0.68	0.41	-0.15	0.24	-0.19
Other Current Assets	0.48	0.48	0.72	0.46	0.62	0.01	-0.91	0.48	0.0	0.58	-0.21	0.41	0.85	-0.11		0.7	-0.06	0.62	0.44	-0.08	0.14	0.16	-0.22	0.56	0.69	-0.25
Other Stockholder Equity	0.8	0.27	0.66	0.82	0.74	-0.38	-0.77	0.71	0.39	0.77	-0.05	0.64	0.65	-0.43	0.7		-0.39	0.74	0.66	-0.22	-0.03	-0.29	-0.48	0.79	0.45	0.33
Total Liab	-0.28	-0.03	-0.27	-0.58	-0.33	0.37	0.03	-0.33	-0.38	-0.07	-0.55	-0.32	0.11	1.0	-0.06	-0.39		-0.33	-0.33	0.4	0.49	0.7	0.42	-0.13	0.26	-0.2
Property Plant And Equipment Gross	0.53	0.51	0.75	0.56	1.0	-0.22	-0.58	0.78	0.23	0.53	-0.05	0.39	0.58	-0.37	0.62	0.74	-0.33		0.41	-0.18	-0.15	-0.29	-0.38	0.56	0.16	-0.08
Total Current Assets	0.92	0.44	0.57	0.89	0.41	-0.86	-0.36	0.57	0.86	0.62	-0.11	1.0	0.29	-0.37	0.44	0.66	-0.33	0.41		0.03	0.05	-0.07	-0.18	0.57	0.11	0.53
Common Stock Total Equity	-0.15	0.07	0.14	-0.29	-0.18	-0.08	0.06	-0.12	0.08	-0.38	-0.88	0.05	-0.37	0.38	-0.08	-0.22	0.4	-0.18	0.03		0.88	0.62	0.93	-0.5	-0.27	-0.14
Common Stock	-0.04	0.1	0.15	-0.23	-0.15	0.06	-0.18	-0.15	-0.05	-0.21	-0.88	0.05	-0.11	0.46	0.14	-0.03	0.49	-0.15	0.05	0.88		0.79	0.78	-0.33	0.17	-0.16
Short Term Investments	-0.18	0.33	0.06	-0.4	-0.29	0.25	-0.06	-0.25	-0.26	-0.22	-0.7	-0.07	0.02	0.68	0.16	-0.29	0.7	-0.29	-0.07	0.62	0.79		0.65	-0.31	0.34	-0.31
Short Long Term Debt Total	-0.41	0.02	-0.01	-0.51	-0.38	0.08	0.25	-0.33	-0.08	-0.63	-0.73	-0.17	-0.53	0.41	-0.22	-0.48	0.42	-0.38	-0.18	0.93	0.78	0.65		-0.74	-0.36	-0.33
Net Tangible Assets	0.79	0.16	0.35	0.73	0.56	-0.33	-0.63	0.66	0.33	0.96	0.14	0.55	0.8	-0.15	0.56	0.79	-0.13	0.56	0.57	-0.5	-0.33	-0.31	-0.74		0.54	0.48
Current Deferred Revenue	0.28	0.13	0.15	0.17	0.16	0.31	-0.71	0.06	-0.32	0.54	-0.08	0.09	0.8	0.24	0.69	0.45	0.26	0.16	0.11	-0.27	0.17	0.34	-0.36	0.54		-0.09
Other Assets	0.59	-0.18	-0.13	0.56	-0.08	-0.59	0.1	0.23	0.58	0.48	0.12	0.54	-0.11	-0.19	-0.25	0.33	-0.2	-0.08	0.53	-0.14	-0.16	-0.31	-0.33	0.48	-0.09

Click cells to compare fundamentals

Eledon Pharmaceuticals Account Relationship Matchups

Eledon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.9M	197.2M	170.5M	92.8M	125.9M	81.1M
Other Current Liab	813K	973K	2.2M	3.9M	2.5M	2.2M
Total Current Liabilities	1.3M	2.5M	4.4M	6.5M	3.9M	3.7M
Total Stockholder Equity	9.5M	190.6M	164.0M	84.2M	83.4M	60.7M
Property Plant And Equipment Net	321K	138K	768K	739K	365K	278.2K
Net Debt	(8.5M)	(114.1M)	(84.1M)	(55.7M)	(4.2M)	(4.4M)
Retained Earnings	(57.6M)	(80.4M)	(114.9M)	(202.9M)	(243.2M)	(231.0M)
Accounts Payable	329K	1.4M	1.8M	2.2M	967K	1.0M
Cash	8.8M	114.2M	84.8M	56.4M	4.6M	4.4M
Non Current Assets Total	960K	81.6M	82.2M	33.3M	69.8M	73.3M
Non Currrent Assets Other	639K	383K	400K	150K	186K	309.2K
Cash And Short Term Investments	8.8M	114.2M	84.8M	56.4M	51.1M	53.7M
Common Stock Shares Outstanding	655.5K	1.5M	14.8M	14.3M	24.6M	25.9M
Liabilities And Stockholders Equity	10.9M	197.2M	170.5M	92.8M	125.9M	81.1M
Non Current Liabilities Total	144K	4.1M	2.2M	2.1M	38.6M	40.5M
Other Current Assets	54K	38K	3.5M	3.1M	5.0M	5.3M
Other Stockholder Equity	67.0M	271.0M	278.9M	287.0M	326.6M	166.9M
Total Liab	1.5M	6.6M	6.6M	8.6M	42.5M	44.6M
Property Plant And Equipment Gross	321K	138K	768K	739K	365K	278.2K
Total Current Assets	10.0M	115.6M	88.3M	59.5M	56.1M	56.0M
Common Stock Total Equity	7K	9K	13K	15K	13.5K	12.8K
Common Stock	9K	13K	15K	14K	24K	13.1K
Net Tangible Assets	12.6M	9.5M	109.6M	83.0M	95.4M	100.2M
Property Plant Equipment	14K	321K	138K	768K	883.2K	927.4K
Net Invested Capital	9.5M	190.6M	164.0M	84.2M	83.4M	88.9M
Net Working Capital	8.6M	113.1M	83.9M	53.0M	52.2M	53.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Eledon Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eledon Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eledon Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eledon Pharmaceuticals Stock:

How To Invest In Eledon

Details

Is Eledon Stock a good investment?

Details

What is Eledon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.

Note that the Eledon Pharmaceuticals information on this page should be used as a complementary analysis to other Eledon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for Eledon Stock analysis

When running Eledon Pharmaceuticals' price analysis, check to measure Eledon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eledon Pharmaceuticals is operating at the current time. Most of Eledon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eledon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eledon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eledon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Transaction History View history of all your transactions and understand their impact on performance
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios

Is Eledon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.64)

Return On Assets

(0.30)

Return On Equity

(0.48)

The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eledon Common Stock Shares Outstanding vs Short Long Term Debt Total Analysis

Common Stock Shares Outstanding vs Short Long Term Debt Total

Common Stock Shares Outstanding vs Short Long Term Debt Total Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Short Long Term Debt Total

Eledon Pharmaceuticals fundamental ratios Correlations

Eledon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eledon Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Eledon Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Net Tangible Assets	+ 0.96	Non Current Assets Total
Total Stockholder Equity	+ 0.94	Total Assets
Short Long Term Debt Total	+ 0.93	Common Stock Total Equity

Cash	- 1.0	Net Debt
Other Current Assets	- 0.91	Retained Earnings
Common Stock	- 0.88	Non Currrent Assets Other
Common Stock Total Equity	- 0.88	Non Currrent Assets Other
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.86	Net Debt